Everything below concerns incretin. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2025-08-22. Numbers and descriptions here follow the published literature rather than marketing material.
Development began in the early 2010s with the goal of extending GLP-1 activity beyond the brief window achieved by native peptide infusion. The earliest approved formulation was a subcutaneous injection given once weekly. A later oral tablet pairs the peptide with an absorption enhancer, sodium N-(8-[2-hydroxybenzoyl] amino) caprylate, usually shortened to SNAC. That carrier lowers local pH and helps the peptide cross gastric tissue. Both routes deliver the same active molecule.
Semaglutide is a synthetic peptide analog of human glucagon-like peptide-1, a gut hormone released after meals. Its backbone retains the GLP-1 sequence but incorporates two substitutions that slow enzymatic breakdown by dipeptidyl peptidase-4. A short polyethylene glycol linker and a C18 fatty diacid are attached to the peptide chain, allowing the molecule to bind serum albumin and remain in circulation far longer than the native hormone. The result is a circulating half-life measured in days rather than the minutes typical of endogenous GLP-1.
Receptor activation occurs at GLP-1 receptors distributed across pancreatic islets, the hypothalamus, and the gastrointestinal tract. Binding triggers G protein signaling that raises cyclic AMP and enhances glucose-dependent insulin release. Because the effect depends on prevailing glucose levels, insulin secretion does not rise when blood sugar is already low. Signaling in the brain and gut also influences appetite and gastric emptying, which is why the compound appears in both metabolic and weight-related research literature.
Certificate of analysis documents from suppliers typically report purity by chromatographic area, water content, and counter-ion identity. Independent verification is advisable because reported values can be generated under differing conditions. Impurity profiles matter for research use, where aggregates, deamidation products, and residual solvents may influence experimental results. Container, lot, and chain-of-custody records support traceability. Analytical results are method-dependent, so comparisons between laboratories require the same procedure and reference standards.
Lyophilized peptide material is typically stored at or below -20 °C, with -80 °C used for longer-term archives. Vials should remain sealed and desiccated because moisture promotes aggregation and hydrolysis. Repeated freeze-thaw cycles are avoided since they can alter peptide conformation and reduce recovery. Once reconstituted, solutions are generally kept at 2-8 °C and used within a defined window. Stability beyond those windows depends on buffer composition and concentration, and exact limits are product-specific rather than universal.
Identity and purity are assessed with reversed-phase high-performance liquid chromatography, which separates the peptide from related impurities by hydrophobicity. Mass spectrometry confirms molecular weight and detects truncation or modification products. Peptide mapping after enzymatic digestion verifies the amino acid sequence. Quantitation is often performed by LC-MS/MS or by immunoassay, and the two approaches can give different values because they measure different things. Method validation parameters such as accuracy, precision, and limit of quantitation are reported alongside results.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide, GLP-1 receptor agonist | Not a small molecule |
| Backbone substitutions | Non-natural residue at position 8, arginine at position 34 | Slows enzymatic cleavage |
| Side chain | C18 fatty diacid with PEG linker | Enables albumin binding |
| Approximate molecular mass | 4114 Da | Varies slightly with salt form |
| Reported half-life | About one week | Longer than native GLP-1 by orders of magnitude |
The compound binds the GLP-1 receptor on pancreatic beta cells and other tissues, activating a G-protein signaling cascade that raises intracellular cyclic AMP. This action increases glucose-dependent insulin secretion when blood glucose is elevated, while binding also slows gastric emptying and reduces glucagon release. In the central nervous system, receptor activation in the hypothalamus and brainstem contributes to reduced appetite. The fatty acid chain binds albumin, which protects the peptide from renal filtration and enzymatic degradation. This albumin binding is central to its extended circulation time.
Native GLP-1 is degraded rapidly by dipeptidyl peptidase-4. Semaglutide resists this cleavage because alanine at position 8 is replaced by alpha-aminoisobutyric acid. A second substitution at position 34 introduces arginine, which further stabilizes the peptide. The most distinctive modification is a spacer and C18 fatty diacid attached at lysine 26, enabling strong albumin affinity. These three changes together produce a half-life measured in days rather than minutes, and the same structural logic underlies other long-acting analogs in this class.
Semaglutide is a synthetic peptide analog of glucagon-like peptide-1, a hormone released from intestinal L-cells after food intake. It contains 31 amino acids and differs from native GLP-1 through modifications that slow enzymatic breakdown. The peptide was developed to extend the short circulating half-life of endogenous GLP-1, which is measured in minutes. Researchers introduced the compound in the early 2010s. Two backbone changes and a fatty acid side chain define its structure, distinguishing it from earlier GLP-1 receptor agonists.
As a peptide, semaglutide is sensitive to conditions that break amide bonds or modify side chains. Deamidation of asparagine and glutamine residues, oxidation of methionine and tryptophan, and non-covalent aggregation are the main degradation routes described in published stability work. Rate depends strongly on pH, buffer species, ionic strength, temperature and exposure to light. Formulators therefore choose a defined solution pH and often add excipients such as phosphate buffer, propylene glycol and phenol, each of which plays a separate role in pH control, tonicity or preservation.
Storage guidance for the finished injectable product distinguishes the unused state from the in-use state. Before first use, pens are kept refrigerated between 2 and 8 degrees Celsius, protected from light, and never frozen, since freezing can disrupt the peptide or the device. After first use, label instructions in several markets permit storage at room temperature up to about 30 degrees Celsius for a limited number of days. Solid research-grade material is normally held at or below minus 20 degrees Celsius, often with desiccant, and allowed to equilibrate before opening.
GLP-1 receptors are expressed on pancreatic beta cells, in the gut, and in several brain regions. Receptor activation raises cyclic AMP, enhances glucose-dependent insulin secretion, and suppresses glucagon release when blood glucose is high. Effects on gastric emptying and on hypothalamic appetite circuits reduce energy intake. Because insulin release remains glucose-dependent, the risk of hypoglycemia is low when the drug is used alone. The precise contribution of each pathway to body weight change in humans remains an area of active investigation.
Clinical studies of semaglutide generally measure glycated hemoglobin, fasting plasma glucose, body weight, and composite cardiovascular endpoints. The SUSTAIN program enrolled adults with type 2 diabetes, while the STEP program focused on obesity without diabetes. Administration follows a stepwise escalation schedule designed to limit gastrointestinal effects during the first weeks. Reported outcomes include mean percentage weight change, the proportion of participants reaching defined weight-loss thresholds, and rates of nausea, vomiting, and diarrhea. Long-term data on durability after treatment stops are still limited and remain a topic of ongoing research.
Semaglutide is a synthetic peptide analog of human glucagon-like peptide-1, developed by Novo Nordisk and first approved in 2017 for type 2 diabetes. It belongs to the incretin mimetic class, a group of agents that reproduce the glucose-dependent actions of endogenous GLP-1. The molecule was engineered to resist degradation by dipeptidyl peptidase-4 and to bind serum albumin, extending its half-life from minutes to roughly one week. Approval for chronic weight management followed in 2021, based on large cardiovascular and obesity outcome trials.
Handling guidance for research quantities calls for single-use aliquots, an inert atmosphere where practical, and avoidance of repeated freeze-thaw cycles that accelerate aggregation. Certificates of analysis typically report purity by peak area, water content, counter-ion identity, and residual solvent levels. In the scientific literature the compound is usually described by its full amino acid sequence, its registry number, or its structural class rather than by any proprietary label. Reporting standards vary between journals, and reviewers increasingly request raw chromatograms alongside tabulated purity figures. Whether current purity thresholds are adequate for every experimental context is debated.
Reversed-phase high-performance liquid chromatography with ultraviolet detection is the dominant approach for peptide purity assessment, usually paired with mass spectrometry to confirm molecular mass and sequence. Peptide mapping by enzymatic digestion and tandem mass spectrometry locates modifications such as deamidation and oxidation. Quantitation in plasma matrices can be performed by LC-MS/MS after solid-phase extraction. Method validation follows general guidance on accuracy, precision, linearity, and limits of detection. Comparability of results between laboratories, when no shared reference standard is available, remains an open question.
Stability studies focus on deamidation of asparagine and glutamine residues, oxidation of methionine, and aggregation into higher-order species. The fatty acid side chain adds susceptibility to oxidative change and can promote self-association at high concentration. Lyophilised material is comparatively robust when kept cold and dry, while aqueous solutions require refrigeration and protection from light. Forced degradation experiments under heat, acid, base, and peroxide conditions establish the specificity of each analytical method. Which degradation route dominates under real storage conditions depends on the formulation and stays formulation-specific.
In 1965, with at least 500 shareholders and on the cusp of bankruptcy, National Semiconductor went "marginally" publicly traded through Pink Sheets at a starting price of $3. Alan Lopato was the market maker with a list of significant shareholders. Due to Rothlein's lack of belief in integrated circuits, and before Sporck was hired, Jack Hegarty replaced Dr Rothlein as CEO, and Don Lucas became chairman, immediately followed by Peter Sprague becoming chairman. In 1966, Sprague hired five top executives away from Fairchild, among whom were Charles E. Sporck, Pierre Lamond, Don Valentine, Floyd Kvamme. At the time of Sporck's hiring, Robert Noyce was de facto head of semiconductor operations at Fairchild and Sporck was his operations manager. Sporck was appointed president and CEO of National. To make the deal better for Sporck's hiring and appointment at half his former salary at Fairchild, Sporck was allotted a substantial share of National's stock. Sporck also brought over three other people from TI, Perkin-Elmer, and Hewlett-Packard to form a new eight-man team at National Semiconductor. The group was allotted 9.6% of the company's stock and after the deal was announced, the stock soared from $3-$4 to $24. Sporck had been Widlar's superior at Fairchild before Widlar left Fairchild to join Molectro after a compensation dispute with Sporck. In 1968, National shifted its headquarters from Danbury, Connecticut, to Santa Clara, California. However, like many companies, National retained its registration as a Delaware corporation, for legal and financial expediency.
==== Trilayer ==== An electric field can change trilayer graphene's crystal structure, transforming its behavior from metal-like into semiconductor-like. A sharp metal scanning tunneling microscopy tip was able to move the domain border between the upper and lower graphene configurations. One side of the material behaves as a metal, while the other side behaves as a semiconductor. Trilayer graphene can be stacked in either Bernal or rhombohedral configurations, which can exist in a single flake. The two domains are separated by a precise boundary at which the middle layer is strained to accommodate the transition from one stacking pattern to the other. Silicon transistors are either p-type or n-type, whereas graphene can operate as both. This lowers costs and is more versatile. The technique provides the basis for a field-effect transistor. In trilayer graphene, the two stacking configurations exhibit different electronic properties. The region between them consists of a localized strain soliton where the carbon atoms of one graphene layer shift by the carbon–carbon bond distance. The free-energy difference between the two stacking configurations scales quadratically with electric field, favoring rhombohedral stacking as the electric field increases. This ability to control the stacking order opens the way to new devices that combine structural and electrical properties.
==== Essays on fascism ==== Starting with his 1947 essay Wagner, Nietzsche and Hitler, Adorno produced a series of influential works to describe psychological fascist traits. One of these works was The Authoritarian Personality (1950), published as a contribution to the Studies in Prejudice performed by multiple research institutes in the US, and consisting of 'qualitative interpretations' that uncovered the authoritarian character of test persons through indirect questions. The books have had a major influence on sociology and remain highly discussed and debated. In 1951 he continued on the topic with his essay Freudian Theory and the Pattern of Fascist Propaganda, in which he said that "Psychological dispositions do not actually cause fascism; rather, fascism defines a psychological area which can be successfully exploited by the forces which promote it for entirely non-psychological reasons of self-interest." In 1952 Adorno participated in a group experiment, revealing residual National Socialist attitudes among the recently democratized Germans. He then published two influential essays, The Meaning of Working Through the Past (1959) and Education after Auschwitz (1966), in which he argued on the survival of the uneradicated National Socialism in the mindsets and institutions of the post-1945 Germany and that there is still a real risk that it could rise again.
Glutathione disulfide (GSSG) is a disulfide derived from two glutathione molecules. In living cells, glutathione disulfide is reduced into two molecules of glutathione with reducing equivalents from the coenzyme NADPH. This reaction is catalyzed by the enzyme glutathione reductase. Antioxidant enzymes, such as glutathione peroxidases and peroxiredoxins, generate glutathione disulfide during the reduction of peroxides such as hydrogen peroxide (H2O2) and organic hydroperoxides (ROOH):
== Screening and design == The process of finding a new drug against a chosen target for a particular disease usually involves high-throughput screening (HTS), wherein large libraries of chemicals are tested for their ability to modify the target. For example, if the target is a novel GPCR, compounds will be screened for their ability to inhibit or stimulate that receptor (see antagonist and agonist): if the target is a protein kinase, the chemicals will be tested for their ability to inhibit that kinase. Another function of HTS is to show how selective the compounds are for the chosen target, as one wants to find a molecule which will interfere with only the chosen target, but not other, related targets. To this end, other screening runs will be made to see whether the "hits" against the chosen target will interfere with other related targets – this is the process of cross-screening. Cross-screening is useful because the more unrelated targets a compound hits, the more likely that off-target toxicity will occur with that compound once it reaches the clinic. It is unlikely that a perfect drug candidate will emerge from these early screening runs. One of the first steps is to screen for compounds that are unlikely to be developed into drugs; for example compounds that are hits in almost every assay, classified by medicinal chemists as "pan-assay interference compounds", are removed at this stage, if they were not already removed from the chemical library.
Sources: en.wikipedia.org
== ADME == A number of phases occur once the drug enters into contact with the organism, these are described using the acronym ADME (or LADME if liberation is included as a separate step from absorption):
== Adverse effects == Nephrotoxicity: Like cisplatin, nephrotoxicity, harm to the kidneys, is the primary dose-limiting factor. However, the nephrotoxicity of nedaplatin has been shown to be less severe than cisplatin. In rats, nedaplatin primarily affected the renal papilla, with papillary necrosis in severe cases. Neurotoxicity: Nedaplatin is widely reported to be neurotoxic, especially to the nerves of the ear. Causing symptoms like numbness and tingling in mild cases, or sensory ataxia in more severe cases. Nausea and vomiting: The emetogenic effects of nedaplatin are commonly managed with prophylactic antiemetics, such as duplex dexamethasone and ondansetron or triplex dexamethasone, ondansetron and aprepitant. Ototoxicity: Nedaplatin is toxic to the nerve and hair cells in the cochlea. In rats, nedaplatin was severely toxic to the nerve cells at a concentration of 10 μM, with damage to hair cells becoming more severe exceeding 100 μM. Neutropenia, leukopenia, anemia and thrombocytopenia (see "Aqupla アクプラ" in External Links): Nedaplatin is toxic to the hemopoietic cells of the bone marrow, combined with reduced levels of erythropoietin, leads to elevated incidence of bone marrow suppression compared to cisplatin. Incidence of severe grades of leukopenia and neutropenia are reported to be higher than cisplatin in treatment combined with radiotherapy. These haematological adverse effects are common in general.
SEAgel (Safe Emulsion Agar gel) is one of a class of high-tech foam materials known as aerogels. It is an excellent thermal insulator and among the least dense solids known. SEAgel was invented by Robert Morrison at the Lawrence Livermore National Laboratory in 1992. SEAgel is made of agar, a carbohydrate material that comes from kelp and red algae, and has a density of 200 mg/cm3. SEAgel can be made lighter than air using hydrogen, causing it to float or hang in the air. It insulates against temperature, noise, and electric current. SEAgel is also completely biodegradable, as it is made entirely of biological material and can even be eaten. Initially, SEAgel starts out as a gelatin-like mixture of agar and water. After it is freeze-dried to remove the water, it is left as a honeycomb of dried agar filled with air, with cell sizes two to three micrometers (2–3 μm) in diameter. SEAgel can have many different uses. Laboratory scientists use SEAgel as targets for X-ray laser experiments because it can be doped with other materials, such as selenium. In order to eliminate the volatile hydrodynamics that occur when a solid-density target explodes before it reaches the density required for lasing, scientists are trying to develop an X-ray laser target with a density that is less than the critical density of laser light (4×1021 electrons/cm3 for 0.53-μm light). SEAgel can help them achieve a more uniform plasma, which will ultimately improve the quality of the X-ray laser beam.
The binding energy of the nucleus is the difference between the rest-mass energy of the nucleus and the rest-mass energy of the neutron and proton nucleons. The binding energy formula includes volume, surface and Coulomb energy terms that include empirically derived coefficients for all three, plus energy ratios of a deformed nucleus relative to a spherical form for the surface and Coulomb terms. Additional terms can be included such as symmetry, pairing, the finite range of the nuclear force, and charge distribution within the nuclei to improve the estimate. Normally binding energy is referred to and plotted as average binding energy per nucleon. According to Lilley, "The binding energy of a nucleus B is the energy required to separate it into its constituent neutrons and protons."
Sources: en.wikipedia.org
Native GLP-1 is degraded within minutes by circulating enzymes. The synthetic version carries substitutions at positions that block enzymatic cleavage, plus a fatty acid side chain that promotes albumin binding. These two changes together extend circulation time from minutes to roughly a week.
Albumin binding keeps a large fraction of the compound in a slowly released reservoir within the bloodstream. Plasma levels decline gradually rather than falling sharply after each administration. That profile supports dosing intervals measured in days instead of hours.
The active peptide sequence is the same in both formats. The oral version adds an absorption enhancer that is not present in the injected solution. Differences in excipients and formulation affect uptake rather than the identity of the active molecule.
The lyophilized powder is dissolved in a suitable solvent, often sterile water or a buffered diluent, with gentle mixing rather than vigorous shaking. Foaming and shear should be avoided because they can promote aggregation. The resulting solution is then stored cold and protected from light.